PL1917026T3 - Lipidowany czynnik tkankowy do stosowania jako środek do miejscowego zapobiegania krwotokom - Google Patents

Lipidowany czynnik tkankowy do stosowania jako środek do miejscowego zapobiegania krwotokom

Info

Publication number
PL1917026T3
PL1917026T3 PL06776572T PL06776572T PL1917026T3 PL 1917026 T3 PL1917026 T3 PL 1917026T3 PL 06776572 T PL06776572 T PL 06776572T PL 06776572 T PL06776572 T PL 06776572T PL 1917026 T3 PL1917026 T3 PL 1917026T3
Authority
PL
Poland
Prior art keywords
tissue factor
lipidated tissue
antihemorrhagic agent
topical
topical antihemorrhagic
Prior art date
Application number
PL06776572T
Other languages
English (en)
Inventor
Egea Javier Pedreño
Catas S Luis Caveda
Original Assignee
Thrombotargets Europe S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrombotargets Europe S L filed Critical Thrombotargets Europe S L
Publication of PL1917026T3 publication Critical patent/PL1917026T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL06776572T 2005-08-03 2006-08-02 Lipidowany czynnik tkankowy do stosowania jako środek do miejscowego zapobiegania krwotokom PL1917026T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05380179A EP1749536A1 (en) 2005-08-03 2005-08-03 Activated factor X stimulants as new antihemorrhagic agents for topical use
PCT/EP2006/007660 WO2007014771A1 (en) 2005-08-03 2006-08-02 Stimulators of factor x activated (fxa) as new topical antihemorrhagic agents
EP06776572.7A EP1917026B9 (en) 2005-08-03 2006-08-02 Lipidated tissue factor for use as topical antihemorrhagic agent

Publications (1)

Publication Number Publication Date
PL1917026T3 true PL1917026T3 (pl) 2014-08-29

Family

ID=35916272

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06776572T PL1917026T3 (pl) 2005-08-03 2006-08-02 Lipidowany czynnik tkankowy do stosowania jako środek do miejscowego zapobiegania krwotokom

Country Status (13)

Country Link
EP (3) EP1749536A1 (pl)
JP (2) JP5268638B2 (pl)
KR (1) KR101362993B1 (pl)
CN (1) CN101291686B (pl)
AU (1) AU2006274979B2 (pl)
BR (1) BRPI0616535B8 (pl)
CA (1) CA2617534C (pl)
DK (1) DK1917026T3 (pl)
ES (1) ES2468225T3 (pl)
HK (1) HK1119569A1 (pl)
PL (1) PL1917026T3 (pl)
TW (2) TW200744633A (pl)
WO (2) WO2007014772A2 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772371B2 (en) * 2005-08-03 2010-08-10 Thrombotargets Corporation Stimulators of Factor X activated (FXa) as new topical antihemorrhagic agents
EP2745852A1 (en) * 2012-12-21 2014-06-25 Thrombotargets Europe, S.L. Sealant compositions
EP2759305A1 (en) * 2013-01-24 2014-07-30 Thrombotargets Europe, S.L. Hemostatic compositions
CN110133303B (zh) * 2019-05-13 2023-04-07 深圳优迪生物技术有限公司 凝血酶原时间测定试剂及其应用
CN112433057B (zh) * 2020-11-10 2023-06-09 北京美创新跃医疗器械有限公司 一种狼疮抗凝物的筛选试剂及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721618A (en) * 1983-06-27 1988-01-26 Queen's University At Kingston Method for controlling bleeding
EP0266993B1 (en) * 1986-11-04 1995-04-05 Genentech, Inc. Method and therapeutic compositions for the treatment of bleeding disorders
US5017556A (en) * 1986-11-04 1991-05-21 Genentech, Inc. Treatment of bleeding disorders using lipid-free tissue factor protein
US6239101B1 (en) * 1989-07-05 2001-05-29 Oklahoma Medical Research Foundation Thrombin binding polypeptides
US6238875B1 (en) * 1991-03-12 2001-05-29 The Scripps Research Institute Diagnostic methods useful in the characterization of lymphoproliferative disease characterized by increased EPR-1
WO1993009804A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
WO1994002172A1 (en) * 1992-07-24 1994-02-03 Oklahoma Medical Research Foundation Blockade of protein c activation reduces microvascular surgical blood loss
US5441759A (en) * 1992-09-03 1995-08-15 Sherwood Medical Company Method to stabilize TDMAC heparin coating
AU716282B2 (en) * 1995-06-07 2000-02-24 Johnson & Johnson Research Pty. Limited CDR-grafted anti-tissue factor antibodies and methods of use thereof
JP2002520053A (ja) * 1998-07-15 2002-07-09 ジェネンテック・インコーポレーテッド 凝固因子ｆｖｉｉ／ｆｖｉｉａに対する向上した親和性を持つ組織因子タンパク質変異体
EP1051620B1 (en) * 1998-10-30 2006-06-07 Jonathan L. Miller Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein ib alpha
AU2002211686A1 (en) * 2000-10-13 2002-04-22 On Site Gas Systems, Inc. Bandage using molecular sieves
US7015193B2 (en) * 2001-04-20 2006-03-21 University Of Vermont Compositions and methods to control bleeding
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
WO2004039842A2 (en) * 2002-10-31 2004-05-13 Novo Nordisk A/S Humanized tissue factor antibodies
CA2570566A1 (en) * 2004-06-25 2006-01-12 Altor Bioscience Corporation Production of tissue factor in plants

Also Published As

Publication number Publication date
ES2468225T3 (es) 2014-06-16
KR20080043324A (ko) 2008-05-16
CN101291686B (zh) 2013-03-13
EP1917026B1 (en) 2014-03-05
BRPI0616535B8 (pt) 2021-05-25
WO2007014771A1 (en) 2007-02-08
AU2006274979B2 (en) 2012-12-13
BRPI0616535B1 (pt) 2019-11-12
BRPI0616535A2 (pt) 2011-06-21
JP2009503008A (ja) 2009-01-29
EP1917026A1 (en) 2008-05-07
TW200744628A (en) 2007-12-16
CA2617534A1 (en) 2007-02-08
DK1917026T3 (da) 2014-06-10
JP5268638B2 (ja) 2013-08-21
ES2468225T9 (es) 2014-10-24
JP2009503009A (ja) 2009-01-29
CA2617534C (en) 2016-07-05
TW200744633A (en) 2007-12-16
KR101362993B1 (ko) 2014-02-21
WO2007014772A2 (en) 2007-02-08
HK1119569A1 (en) 2009-03-13
TWI441645B (zh) 2014-06-21
EP1749536A1 (en) 2007-02-07
AU2006274979A1 (en) 2007-02-08
WO2007014772A3 (en) 2007-04-12
EP1917026B9 (en) 2014-06-18
CN101291686A (zh) 2008-10-22
EP1915175A2 (en) 2008-04-30

Similar Documents

Publication Publication Date Title
TWI366469B (en) Emulsified skin agent for external use
ZA200708438B (en) External preparation for skin
HK1122991A1 (en) External preparation for skin
ZA200803150B (en) Topical Formulations
ZA200800006B (en) Composition for treating skin lesions
GB2451597B (en) Compositions for topical treatment
EP1938808A4 (en) PREPARATION FOR TOPICAL APPLICATION
HK1119569A1 (en) Lipidated tissue factor for use as topical antihemorrhagic agent
EP1854354A4 (en) AGENT INTENDED TO ENHANCE ANTISEPTIC POWERS
GB2416693B (en) Composition for reducing blood lipids
EP1957080A4 (en) TOPICAL GLUCOCORTICOSTEROID FORMULATIONS
EP1895843A4 (en) MICOGEL TOPICAL FORMULAS
ZA200605597B (en) Compositions for use with skin
GB0516610D0 (en) Compounds for use in therapy
ZA201003835B (en) Therapeutic agent for ulcer
AU3435P (en) Kakegawa S63 Calibrachoa hybrid
AU3235P (en) Balcabwite Calibrachoa hybrid
AU3280P (en) USCALI4 Calibrachoa hybrid
AU3281P (en) USCALI28 Calibrachoa hybrid
AU3279P (en) USCALI11 Calibrachoa hybrid
AU3234P (en) Balcabcher Calibrachoa hybrid
AU3236P (en) Balcabrose Calibrachoa hybrid
AU3233P (en) Balcabpurp Calibrachoa hybrid
AU3238P (en) Balcabred Calibrachoa hybrid
GB0517519D0 (en) Topical prostaglandin formulation